Clearmind Medicine Inc. (CMND) shareholders
Close on Nov 13, 2026Market cap $716.08KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Richard Abbe Joint filing with Iroquois Capital Management, LLC (9.99%), Kimberly Page (9.99%) | 346,667 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CMND | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 4,393 | 2.78% | $77.00K | New | 0.00% |
| Citadel Advisors LLC | 1,464 | 0.93% | $25.76K | New | 0.00% |
| AdvisorShares Investments LLC | 146 | 0.09% | $2.57K | New | 0.00% |
| Morgan Stanley | 88 | 0.06% | $1.54K | New | 0.00% |
| Royal Bank of Canada | 36 | 0.02% | $1.00K | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 0 | 0.00% | $2 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 3.9% | 6 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 7 | 0M | 0M |
| Q3 2025 | 7 | 0M | 0.1% | 2 / 1 | 0 / 4 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.1% | 3 / 1 | 1 / 1 | 0M | 0M |
| Q1 2025 | 7 | 0M | 0.1% | 1 / 1 | 0 / 3 | 0M | 0M |
| Q4 2024 | 9 | 0M | 0.1% | 3 / 2 | 1 / 2 | 0M | 0M |
| Q3 2024 | 8 | 0M | 0.1% | 5 / 1 | 0 / 1 | 0M | 0M |
| Q2 2024 | 4 | 0M | 0.0% | 1 / 1 | 0 / 1 | 0M | 0M |
| Q1 2024 | 4 | 0M | 0.0% | 3 / 1 | 0 / 0 | 0M | 0M |
| Q4 2023 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Financial Lp Hrt | 10% owner | 184,845 | 116.93% | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Financial Lp Hrt 10% owner | Jun 16, 2026 | Sale | −22,139 | $3.31 | $73.28K | 81,353 |
| Financial Lp Hrt 10% owner | Jun 15, 2026 | Sale | −3,183 | $3.32 | $10.57K | 103,492 |
| Financial Lp Hrt 10% owner | Jun 12, 2026 | Sale | −2,102 | $3.36 | $7.06K | 106,675 |
| Financial Lp Hrt 10% owner | Jun 11, 2026 | Sale | −225,191 | $0.12 | $27.02K | 1,838,075 |
| Financial Lp Hrt 10% owner | Jun 10, 2026 | Buy | +2,159,052 | $0.15 | $323.86K | 2,063,266 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Clearmind Medicine's stock actually held short. Settlement fails (shares not delivered on time) peaked at 56,198 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?